Low-Dose Naltrexone (LDN)


Mu-opioid antagonist (low-dose immunomodulatory use)

Abstract

Mechanism is multifactorial and incompletely characterized: brief, transient mu-opioid antagonism (only 4 to 6 hours per dose) triggers compensatory upregulation of endogenous opioid synthesis and receptor expression, producing a paradoxical increase in opioid-mediated tone over baseline; secondary TLR4 antagonism on microglia attenuates neuroinflammation. Off-label LDN use in multiple sclerosis, Crohn disease, fibromyalgia, complex regional pain syndrome, and Hashimoto thyroiditis is supported by small clinical trials with mixed methodology. Plasma half-life is approximately 4 hours. Used as a research compound for paradoxical opioid pharmacology and neuroimmune modulation.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph